资讯

来自MSN2 个月
OS Therapies’s HER2 therapy prevents lung cancer recurrence in 33% patients
OS Therapies’s HER2-immunotherapy met the primary endpoint in a Phase IIb trial in patients with recurrent, fully resected, lung metastatic (METS) osteosarcoma. The Phase IIb trial (NCT04974008 ...
Seeking Alpha11 天
OS Therapies Provides Regulatory Update on Rare Pediatric Cancer Immunotherapy Candidate ...
Potential Treatment Response Biomarkers from Canine Osteosarcoma Program The ... in prevention of recurrence of metastases, metastasis treatment (lung resection is not standard of care in canines ...